BioTime has contributed to a $10m round for AgeX, an age-related disease treatment developer it has spun out that is now valued at $68m.
AgeX Therapeutics, an age-related disease therapy developer spun out of biotechnology company BioTime, has closed $10m in funding from investors including its parent company.
Investment firm IBS Capital also participated in the round, as did angel investors including Jim Mellon, John Mauldin and BioTime chairman Alfred Kingsley.
AgeX is looking to create treatments for aging and age-related diseases using cellular immortality and regenerative biology technology licensed from BioTime.
The company’s first three clinical areas involve applying pluripotent stem cell-derived brown…
